You are here:

Bristol-Myers Squibb Pharmaceuticals Ltd

Name SMC ID No Status Sub. Type
abatacept (Orencia) 618/10 Not Recommended Non submission
abatacept (Orencia) 618/10 Superseded Abbreviated Submission
abatacept (Orencia) 719/11 Not Recommended Full submission
abatacept (Orencia) 719/11 Superseded Resubmission
abatacept (Orencia) 1230/17 Not Recommended Non submission
abatacept (Orencia) 1287/17 Not Recommended Non submission
abatacept 125mg/mL solution for subcutaneous injection in a pre-filled syringe (Orencia®) 888/13 Superseded Abbreviated Submission
abatacept 250mg powder for concentrate for solution (Orencia) 400/07 Superseded Full submission
apixaban (Eliquis) 741/11 Accepted Full submission
apixaban (Eliquis) 836/13 Accepted Full submission
aripiprazole (Abilify) 498/08 Not Recommended Full submission
Aripiprazole (Abilify®) 95/04 Accepted Full submission
Aripiprazole (Abilify®) 187/05 Restricted Abbreviated Submission
aripiprazole (Ablify) 498/09 Not Recommended Resubmission
aripiprazole IM (Abilify) 522/08 Accepted Abbreviated Submission
aripiprazole tablets, orodisperible tablets and oral solution (Abilify) 630/10 Restricted Abbreviated Submission
atazanavir & cobicistat (Evotaz) 1098/15 Accepted Abbreviated Submission
atazanavir (Reyataz) 520/08 Accepted Full submission
Atazanavir (Reyataz®) 120/04 Restricted Full submission
atazanavir (Reytaz) 656/10 Accepted Abbreviated Submission
belatacept (Nulojix) 786/12 Not Recommended Full submission
daclatasvir (Daklinza) 1002/14 Restricted Full submission
dapagliflozin (Forxiga) 799/12 Restricted Full submission
dasatinib (Sprycel) 1170/16 Accepted Full submission
dasatinib (Sprycel) Second Line Treatment 370/07 Accepted Resubmission
dasatinib 20mg, 50mg, 70mg tablets (Sprycel) 371/07 Not Recommended Full submission
dasatinib 20mg, 50mg, 70mg tablets (Sprycel) 370/07 Superseded Full submission
efavirenz (Sustiva) 1125/15 Accepted Abbreviated Submission
efavirenz / emtricitabine / tenofovir disoproxil fumarate (Atripla) 442/08 Accepted Abbreviated Submission
elotuzumab (Empliciti) 1183/16 Not Recommended Non submission
entecavir (Baraclude) 747/11 Not Recommended Full submission
entecavir (Baraclude) 1049/15 Restricted Abbreviated Submission
entecavir, 0.5 and 1mg tablets (Baraclude) 320/06 Accepted Full submission
ipilimumab (Yervoy) 779/12 Not Recommended Full submission
ipilimumab (Yervoy) 779/12 Accepted Resubmission
ipilimumab (Yervoy) 997/14 Accepted Full submission
nivolumab (Opdivo) 1120/16 Not Recommended Full submission
nivolumab (Opdivo) 1120/16 Restricted Resubmission
nivolumab (Opdivo) 1144/16 Accepted Full submission
nivolumab (Opdivo) 1187/16 Restricted Full submission
nivolumab (Opdivo) 1188/16 Not Recommended Full submission
nivolumab (Opdivo) 1188/16 Accepted Resubmission
nivolumab (Opdivo) (SCCHN) 1261/17 Restricted Full submission
nivolumab (Opdivo) for cHL 1240/17 Accepted Full submission
nivolumab (Opdivo) for non-squamous NSCLC 1180/16 Restricted Full submission
nivolumab (Opvido) 1285/18 Not Recommended Full submission
Paracetamol 500mg/50ml intravenous infusion (Perfalgan®) 172/05 Accepted Abbreviated Submission
Paracetamol infusion (Perfalgan®) 137/04 Accepted Full submission
saxagliptin (Onglyza) 958/14 Not Recommended Non submission
saxagliptin (Onglyza) 603/10 Restricted Full submission
saxagliptin (Onglyza) 918/13 Restricted Full submission
saxagliptin + metformin (Komboglyze) 870/13 Restricted Abbreviated Submission
saxagliptin metformin (Kombogylze) 929/13 Accepted Abbreviated Submission